Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer

To the Editor: In their report on the AEGEAN trial, Heymach et al. (Nov. 2 issue)(1) found that perioperative durvalumab for resectable non-small-cell lung cancer significantly extended event-free survival. In Table 3, the incidence of adverse events leading to discontinuation of durvalumab or placebo was 12.0% (48 of 401) in the durvalumab group and 6.0% (24 of 398) in the placebo group. The authors commented that the treatment "had no detrimental effect on the completion of neoadjuvant chemotherapy or surgery." However, we noticed a significant between-group difference in these events (P=0.004 by Fisher's exact test). We then performed a brief . . .